Botulinum Neurotoxins for the Treatment of Chronic Pain and Headaches
A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Bacterial Toxins".
Deadline for manuscript submissions: 31 October 2025 | Viewed by 236
Special Issue Editor
Interests: neurobiology of primary and secondary headaches
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We invite researchers to contribute to the growing body of knowledge on the role of botulinum toxins in the treatment of headaches and pain. While botulinum toxin A is currently approved for the treatment of chronic migraine, its use has expanded widely as an off-label therapy for various other pain conditions, offering promising outcomes for patients who struggle with these complex disorders. Current clinical trials from various industries and research groups in the field of botulinum toxins are exploring the broader potential of their products in treating both episodic and chronic migraine, as well as exploring novel applications in the field of other chronic pain conditions. Further research offering clarity on the mechanism of action of botulinum toxins in sensory systems and their CNS pathways is urgently needed. Looking ahead, the future of botulinum toxin therapies is particularly exciting with the development of recombinant botulinum toxins and non-paralytic formulations. These advancements may further enhance treatment precision and patient outcomes, offering new hope for those who have not found adequate relief through conventional therapies. As the field continues to evolve, your contributions to this important area of research could shape the next generation of headache pain management solutions.
Dr. Anna P. Andreou
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- botulinum toxins
- migraine
- chronic pain
- pain management
- headaches
- neuropathic pain
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
